Nanoparticle-Based Drug Delivery in Cancer Therapy: Current Progress and Challenges
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 98
Special Issue Editors
Interests: small-molecule nanoparticle; targeting drug delivery; nanomaterial-based immunoregulator
Special Issues, Collections and Topics in MDPI journals
Interests: drug delivery; peptide-based nanoparticles; magnetic-propelled cell robots
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer remains one of the most complex and challenging diseases worldwide. Among the approaches being explored, nanoparticle-based drug delivery systems have shown promising potential in preclinical research. The unique properties of nanoparticles allow for the targeted delivery at the tumor site, controlled release, and prolonged circulation time of the anticancer agent. The application of nanoparticles not only promises to enhance the therapeutic effect and reduce systemic toxicity but also to overcome drug resistance in cancer treatments. However, challenges such as targeting efficiency, stability, long-term effects, and consistency in manufacturing process hinder their clinical translation.
Therefore, we invite investigators to contribute their original research and review articles that address these challenges and explore innovative nanoparticles. Such contributions should provide new insights and help bridge the gap from bench to clinic in nanoparticle-based cancer therapy.
Dr. Menghuan Tang
Dr. Zhaoqing Cong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticle
- targeted drug delivery
- controlled release
- clinical translation
- drug resistance
- nanomedicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
